New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
10:23 EDTSWHC, RMTI, MTOR, APOL, NWBO, SBGI, UNXL, ACHN, VRTX, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN UNXL SBGI NWBO APOL MTOR RMTI SWHC
News For OHRP;VRTX;ACHN;UNXL;SBGI;NWBO;APOL;MTOR;RMTI;SWHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
08:24 EDTVRTXVertex price target raised to $117 from $109 at Maxim
Maxim raised its price target for Vertex shares to $117 after the company gave an update at the Cystic Fibrosis Conference. The form keeps a Buy rating on the stock.
05:59 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 61, Achillion (ACHN) 200 according to iVolatility.
October 9, 2014
12:46 EDTAPOLDoE policy changes a negative for select Education stocks, says Deutsche Bank
Subscribe for More Information
09:33 EDTVRTXVertex says VX-661 Phase 2 study fully enrolled
Subscribe for More Information
07:33 EDTRMTIRockwell Medical announces FDA advisory committee review of Triferic
Subscribe for More Information
07:22 EDTVRTXCystic Fibrosis Foundation to hold a conference
Subscribe for More Information
06:08 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 60, Achillion (ACHN) 195 according to iVolatility.
October 8, 2014
16:26 EDTACHNOn The Fly: Closing Wrap
Subscribe for More Information
15:49 EDTACHNAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
13:36 EDTRMTIRockwell Medical November volatility elevated
Subscribe for More Information
10:38 EDTRMTIHigh option volume stocks
High option volume stocks: FRAN RMTI ACM CY CLNY SMH BEAV SIG CTB DUG SHLD
09:38 EDTRMTIActive equity options trading on open
Subscribe for More Information
October 7, 2014
10:56 EDTACHNOptions with increasing implied volatility
Subscribe for More Information
10:02 EDTMTOROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:36 EDTACHNActive equity options trading on open
Subscribe for More Information
09:07 EDTNWBONorthwest Biotherapeutics raises $11.5M through an institutional stock sale
Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
09:05 EDTNWBONorthwest Biotherapeutics enters into $11.5M financing agreement
Subscribe for More Information
07:46 EDTVRTXPTC Therapeutics weakness a buying opportunity, says Oppenheimer
Oppenheimer believes that the Street is underestimating the opportunity for PTC Therapeutics' (PTCT) Translarna in the most severe patients with Cystic fibrosis. The firm thinks the drug is not competitive with, and can potentially be complemented by, therapies from Vertex (VRTX). Oppenheimer views the weakness in PTC as a buying opportunity and keeps its Outperform rating on the shares.
07:32 EDTRMTIRockwell Medical receives $8M in cash via exercise of warrants
Subscribe for More Information
06:54 EDTMTORMeritor initiated with a Neutral at Longbow
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use